X |
Filing Date |
Trade Date |
Ticker |
Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-01-26 | GBIO | Paone Antoinette | COO | S - Sale | $5.56 | -2,695 | 0 | -100% | -$14,984 | ||||||
2023-01-10 | GBIO | Paone Antoinette | COO | S - Sale | $4.57 | -1,865 | 0 | -100% | -$8,523 | ||||||
2023-01-09 | GBIO | Samayoa Phillip | CHIEF STRATEGY OFFICER | S - Sale | $5.11 | -1,865 | 95,819 | -2% | -$9,530 | ||||||
2022-10-27 | GBIO | Paone Antoinette | COO | S - Sale | $5.03 | -2,914 | 0 | -100% | -$14,657 | ||||||
2022-09-29 | GBIO | Paone Antoinette | COO | S - Sale | $5.24 | -2,828 | 0 | -100% | -$14,819 | ||||||
2022-09-19 | GBIO | Rowland Charles A Jr | Dir | P - Purchase | $5.26 | +15,750 | 191,797 | +9% | +$82,845 | ||||||
2022-09-15 | GBIO | Paone Antoinette | COO | S - Sale | $5.32 | -4,610 | 2,828 | -62% | -$24,525 | ||||||
| M | 2022-09-15 | GBIO | Rowland Charles A Jr | Dir | P - Purchase | $5.46 | +50,628 | 176,047 | +40% | +$276,241 | |||||
| M | 2022-09-13 | GBIO | Rowland Charles A Jr | Dir | P - Purchase | $5.22 | +24,384 | 125,419 | +24% | +$127,404 | |||||
| M | 2022-03-09 | GBIO | Nicholson Donald William | Dir | P - Purchase | $4.73 | +10,419 | 113,576 | +10% | +$49,257 | |||||
| M | 2021-09-27 | GBIO | Rhodes Jason P | Dir | S - Sale | $25.40 | -81,088 | 8,279,484 | -1% | -$2,059,519 | |||||
| M | 2021-09-27 | GBIO | Atlas Venture Associates X, L.P. | 10% | S - Sale | $25.40 | -81,088 | 8,279,484 | -1% | -$2,059,519 | |||||
| M | 2021-09-22 | GBIO | Rhodes Jason P | Dir | S - Sale | $26.02 | -134,998 | 8,279,633 | -2% | -$3,511,993 | |||||
| M | 2021-09-22 | GBIO | Atlas Venture Associates X, L.P. | 10% | S - Sale | $26.02 | -134,998 | 8,360,572 | -2% | -$3,511,993 | |||||
| D | 2021-09-14 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $28.07 | -4,500 | 198,154 | -2% | -$126,315 | |||||
| D | 2021-09-10 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $25.97 | -3,000 | 198,154 | -1% | -$77,910 | |||||
| D | 2021-08-23 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $25.04 | -1,500 | 198,154 | -1% | -$37,560 | |||||
| D | 2021-08-10 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $22.63 | -1,500 | 198,154 | -1% | -$33,943 | |||||
| D | 2021-07-12 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $25.03 | -3,000 | 198,154 | -1% | -$75,087 | |||||
| D | 2021-07-08 | GBIO | Kerr Douglas | CHIEF MEDICAL OFFICER | S - Sale+OE | $25.20 | -3,518 | 326,558 | -1% | -$88,670 | |||||
2021-06-24 | GBIO | Rhodes Jason P | Dir | S - Sale | $25.85 | -31,008 | 9,379,484 | 0% | -$801,618 | ||||||
2021-06-24 | GBIO | Atlas Venture Associates X, L.P. | 10% | S - Sale | $25.85 | -31,008 | 608 | -98% | -$801,618 | ||||||
| M | 2021-06-21 | GBIO | Rhodes Jason P | Dir | S - Sale | $25.05 | -185,078 | 9,379,542 | -2% | -$4,635,967 | |||||
| M | 2021-06-21 | GBIO | Atlas Venture Associates X, L.P. | 10% | S - Sale | $25.05 | -185,078 | 31,616 | -85% | -$4,635,967 | |||||
| D | 2021-06-15 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $28.08 | -1,500 | 198,154 | -1% | -$42,120 | |||||
| D | 2021-06-10 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $27.23 | -6,000 | 198,154 | -3% | -$163,380 | |||||
| D | 2021-05-27 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $34.05 | -1,500 | 198,154 | -1% | -$51,075 | |||||
| DM | 2021-05-10 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $30.61 | -9,000 | 198,154 | -4% | -$275,534 | |||||
| D | 2021-05-03 | GBIO | Zimmermann Tracy | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $35.70 | -2,500 | 0 | -100% | -$89,238 | |||||
2021-05-03 | GBIO | McDonough Geoff | Pres, CEO | S - Sale | $35.63 | -10,000 | 1,675,542 | -1% | -$356,335 | ||||||
2021-04-23 | GBIO | McDonough Geoff | Pres, CEO | S - Sale | $35.10 | -10,000 | 1,685,542 | -1% | -$351,000 | ||||||
| D | 2021-04-22 | GBIO | Zimmermann Tracy | CHIEF DEVELOPMENT OFFICER | S - Sale+OE | $33.32 | -2,500 | 0 | -100% | -$83,300 | |||||
| DM | 2021-04-21 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $32.55 | -3,000 | 198,154 | -1% | -$97,650 | |||||
| D | 2021-04-16 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $28.03 | -1,500 | 198,154 | -1% | -$42,045 | |||||
| M | 2021-04-12 | GBIO | Rhodes Jason P | Dir | S - Sale | $25.92 | -140,682 | 10,479,484 | -1% | -$3,646,968 | |||||
| M | 2021-04-12 | GBIO | Atlas Venture Associates X, L.P. | 10% | S - Sale | $25.92 | -140,682 | 9,111,939 | -2% | -$3,646,968 | |||||
| D | 2021-04-12 | GBIO | Stanton Matthew | CHIEF SCIENTIFIC OFFICER | S - Sale+OE | $26.24 | -6,000 | 198,154 | -3% | -$157,446 | |||||
| M | 2021-04-07 | GBIO | Atlas Venture Associates X, L.P. | 10% | S - Sale | $28.20 | -127,095 | 9,252,621 | -1% | -$3,583,860 | |||||
| M | 2021-04-07 | GBIO | Rhodes Jason P | Dir | S - Sale | $28.20 | -127,095 | 10,620,166 | -1% | -$3,583,860 | |||||
| D | 2021-04-05 | GBIO | Kerr Douglas | CHIEF MEDICAL OFFICER | S - Sale+OE | $30.09 | -14,072 | 326,558 | -4% | -$423,451 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |